Evidence map›Paper›PMID 41604577›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination.

Nicholas J Tursi, Colby J Agostino, Jinwei Huang, Toshitha Kannan, Niklas Laenger, Jennifer Londregan, Katlyn Lederer, Michaela Helble, Nicole Bedanova, Cory Livingston and 12 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Nicholas J TursiVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-6752-3402
Colby J AgostinoVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Jinwei HuangVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Toshitha KannanVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Niklas LaengerVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Jennifer LondreganPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Katlyn LedererPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michaela HelbleVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Nicole BedanovaVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Cory LivingstonVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Ebony N GaryVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Madison McCannaVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Marta Tarquis MedinaVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Rumi HabibVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Ignacio Rodriguez RelañoVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Ivan MaillardPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ami PatelVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
David AllmanPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Andrew KossenkovVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Amelia EscolanoVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
Daniel W KulpVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.
David B WeinerVaccine and Immunotherapy Centerthe Wistar Institute, Philadelphia, Pennsylvania, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Vaccine and adjuvant Clinical GMP product development and DNA Technology platform enhancementsU19AI166916 · NIAID · WISTAR INSTITUTE · PI DAVID B. WEINER · 2023 to 2026
$24.0M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
Notch Signaling in AlloimmunityR01AI091627 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PEAR, WARREN S · 2011 to 2025
$6.0M
Immune System Development and RegulationT32AI055428 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ALLMAN, DAVID M, OLIVER, PAULA MARIA · 2003 to 2025
$4.2M
Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomasR01CA278976 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ivan Maillard, Ryan A Wilcox · 2024 to 2026
$1.9M
Commonwealth of Pennsylvania Health Research Formula FundINOVIO Pharmaceuticals SRA21-05NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA278976NCI NIH HHS T32 CA009171NIAID NIH HHS R01 AI091627NIAID NIH HHS T32 AI055428NIAID NIH HHS U19 AI166916NIH HHS R01AI091627NIH HHS R01CA278976NIH HHS T32AI055428NIH HHS T32CA009171NIH IPCAVD U19AI166916The Jill and Mark Fishman FoundationW.W. Smith Charitable Trust Distinguished Professorship in Cancer Research
6 · The paper itself

Abstract

Vaccine approaches capable of eliciting enhanced germinal center (GC) responses would result in improved protective humoral immunity against infectious diseases. Here, we investigate whether a cytokine can be scaffolded onto a self-assembling nanoparticle immunogen to enhance antigen-specific GC responses and B cell maturation. To test this approach, we design chimeric nanoparticles bearing eOD-GT8, a germline-targeting HIV immunogen, and IL-21, a canonical GC cytokine. DNA delivery of these nanoparticle immunoadjuvant complexes (GT8-IL-21-NICs) drives improved serum antibody titers and antigen-specific GC B cell responses in mice. Transcriptomic analysis of eOD-GT8-specific GC B cells demonstrates upregulation of selection-associated gene signatures with GT8-IL-21-NIC immunization. In mice harboring human bnAb precursor heavy and light chain genes, immunization with the GT8-IL-21-NIC leads to increased antibody diversity, clonal expansion, somatic hypermutation, and the acquisition of key antibody mutations. These results highlight IL-21 as a promising genetic adjuvant and demonstrate that NICs may be a valuable tool to improve antigen-specific GC responses and vaccine-induced immunity.

Indexed as

Adjuvants, ImmunologicGerminal CenterInterleukinsNanoparticlesVaccinationAnimalsB-LymphocytesFemaleHumansImmunity, HumoralInterleukin-21MiceNanovaccinesAdjuvants, ImmunologicInterleukin-21InterleukinsNanovaccinesDNA vaccinesgerminal centersgermline targetingHIV vaccinesInterleukin‐21Nanoparticles

Identifiers

PMID41604577
PMCPMC12970240

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.